Emgality Transfer into Breast Milk (P8-15.007)

Methma Udawatta; Min Ji Kim; Kerri Bertrand; Annika Ehrlich; Ayushi Balan; Amy Gelfand; Jeremiah Momper; Christina Chambers; Riley Bove

doi:10.1212/wnl.0000000000216623

June 9, 2026Neurology

Emgality Transfer into Breast Milk (P8-15.007)

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to assess how much of the migraine prevention drug galcanezumab transfers into breast milk.
Analyzed galcanezumab levels in breast milk samples from mothers undergoing treatment.
Ensured proper collection and storage of milk samples to maintain accuracy.
Detectable levels of galcanezumab were found in breast milk, indicating some transfer occurs.
The concentration in breast milk may impact breastfeeding.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Study determines the transfer of galcanezumab into breast milk, implying safety for breastfeeding mothers using the treatment.

Abstract

To determine the transfer of galcanezumab, a monoclonal antibody to calcitonin gene-related peptide (CGRP) used for migraine prevention, into breast milk.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Udawatta et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf393faef96ed7f056043 https://doi.org/10.1212/wnl.0000000000216623

View at Publisher

Ask AI

Bookmark

Share

Emgality Transfer into Breast Milk (P8-15.007)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Emgality Transfer into Breast Milk (P8-15.007)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading